Abstract: A method for manufacturing an electronic device is provided. The method for manufacturing the electronic device includes: providing a substrate with elements disposed thereon and transferring a portion of the elements from the substrate to a driving substrate, wherein transferring the portion of the elements from the substrate to the driving substrate includes: transferring the portion of the elements from the substrate to the driving substrate, which comprises illuminating regions of the substrate overlapped with the portion of the elements by an energy beam, wherein when the substrate is illuminated by the energy beam, the substrate and the driving substrate are separated by a gap.

Abstract: Semiconductor devices including fin-shaped isolation structures and methods of forming the same are disclosed. In an embodiment, a semiconductor device includes a fin extending from a semiconductor substrate; a shallow trench isolation (STI) region over the semiconductor substrate adjacent the fin; and a dielectric fin structure over the STI region, the dielectric fin structure extending in a direction parallel to the fin, the dielectric fin structure including a first liner layer in contact with the STI region; and a first fill material over the first liner layer, the first fill material including a seam disposed in a lower portion of the first fill material and separated from a top surface of the first fill material, a first carbon concentration in the lower portion of the first fill material being greater than a second carbon concentration in an upper portion of the first fill material.

Abstract: A radiotherapy system includes a neutron acceptor, an aerosolization device for aerosolizing the neutron acceptor, and an energy beam generator. A method for treating cancer, including: administering to a subject in need thereof an effective amount of an aerosolized neutron acceptor; and irradiating the subject with neutrons. A method for diagnosing cancer, including: administering to a subject in need thereof an effective amount of an aerosolized radioactive agent; and receiving an energy beam signal from the subject. A method for delivering a neutron receptor to a subject during radiation therapy, including aerosolizing the neutron receptor and administering to the subject an effective amount of the neutron receptor.

Abstract: A method for preparing a benzylamine derivative through amination of a benzylic C—H bond under visible light-induced nickel catalysis is provided. The method includes: weighing and adding an amination reagent, a ruthenium or iridium photosensitizer, a nickel catalyst, a Lewis acid, and a ligand according to a molar ratio to a reaction vessel; under an inert gas atmosphere, adding a solvent, stirring, adding a benzyl-containing alkylate, and irradiating with a visible light source to allow a full reaction; and conducting separation and purification to obtain the benzylamine derivative. The method involves cheap and easily-available raw materials, and has relatively-extensive substrate applicability. In addition, the method has advantages such as mild reaction conditions, a high yield of a target product, small pollution, and a simple reaction operation and post-treatment, and thus is suitable for industrial production.

Abstract: The present disclosure provides a display panel, including: a driving backplane; a light-emitting unit layer located on a side of the driving backplane and comprising at least one light-emitting pixel unit; a metasurface composite structure layer located on a light-exiting side of the light-emitting pixel unit and including at least two metasurface micro-lens structure layers, which are sequentially arranged in a direction away from the light-emitting pixel unit and are independent of each other, where the metasurface micro-lens structure layers are configured to modulate a phase of light incident thereinto so as to converge the light. Embodiments of the present disclosure further provide a method for manufacturing a display panel and a display device.

Abstract: A method for extracting carbon dioxide from a flue gas includes a preparing process, an acid removing process, and a purifying and liquefying process. The preparing process is implemented by collecting the flue gas generated by oxygen-enriched combustion of a glass raw material with methane from a glass furnace. The flue gas includes the carbon dioxide, nitrogen, water vapor, oxygen, fluoric acid compounds, and boric acid compounds. The acid removing process is implemented by performing a first acid removing operation. The first acid removing operation is implemented by using a sodium hydroxide aqueous solution to remove the fluoric acid compounds and the boric acid compounds in the flue gas. The purifying and liquefying process is implemented by using a purifying and liquefying unit to extract the flue gas that already undergoes the acid removing process, so as to obtain liquid carbon dioxide having a purity greater than 99%.

Abstract: Semiconductor devices including fin-shaped isolation structures and methods of forming the same are disclosed. In an embodiment, a semiconductor device includes a fin extending from a semiconductor substrate; a shallow trench isolation (STI) region over the semiconductor substrate adjacent the fin; and a dielectric fin structure over the STI region, the dielectric fin structure extending in a direction parallel to the fin, the dielectric fin structure including a first liner layer in contact with the STI region; and a first fill material over the first liner layer, the first fill material including a seam disposed in a lower portion of the first fill material and separated from a top surface of the first fill material, a first carbon concentration in the lower portion of the first fill material being greater than a second carbon concentration in an upper portion of the first fill material.

Abstract: A method for reducing hyperpigmentation in a subject, comprising administering an effective amount of a pharmaceutical composition to a skin site of a subject in need thereof, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a stilbene compound, for example, a compound of Formula (I) (e.g., Formula (I-A)), or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject and effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.

Abstract: A preparation method of a rhodium octanoate dimer includes the following steps: (1) mixing RhCl3 with an alkali metal octanoate uniformly to get a first solution; (2) adding a reductant into the first solution obtained from step (1), and heating for reflux reaction to get a second solution; (3) adding the second solution obtained from step (2) into deionized water while hot, continuing to stir, and performing a suction filtration to get a crude product; and (4) performing a primary washing, a secondary washing, a filtration, and a drying on the crude product obtained from step (3) to get a rhodium octanoate dimer as a green solid.

Abstract: A method for preparing FDCA with furfural as a raw material includes (1) pretreatment of the furfural: subjecting the furfural and an alcohol compound to an acetalization reaction under catalysis of an acidic ion resin to obtain an acetal compound of the furfural with the alcohol compound; (2) under stirring, adding the acetal compound dropwise to a mixed liquid of an acylation reagent and an ionic liquid (IL) to allow a reaction for 1 h to 2 h, adding a catalyst to continue the reaction for 3 h to 5 h, and subjecting a resulting reaction system to a post-treatment to obtain 5-acylfurfural; and (3) mixing the 5-acylfurfural with hydrogen peroxide, adding a catalyst to allow an oxidation reaction, and after the oxidation reaction is completed, subjecting a product to washing and recrystallization to obtain a white crystal, which is the FDCA.

Abstract: A method for preparing FDCA with furfural as a raw material includes (1) pretreatment of the furfural: subjecting the furfural and an alcohol compound to an acetalization reaction under catalysis of an acidic ion resin to obtain an acetal compound of the furfural with the alcohol compound; (2) under stirring, adding the acetal compound dropwise to a mixed liquid of an acylation reagent and an ionic liquid (IL) to allow a reaction for 1 h to 2 h, adding a catalyst to continue the reaction for 3 h to 5 h, and subjecting a resulting reaction system to a post-treatment to obtain 5-acylfurfural; and (3) mixing the 5-acylfurfural with hydrogen peroxide, adding a catalyst to allow an oxidation reaction, and after the oxidation reaction is completed, subjecting a product to washing and recrystallization to obtain a white crystal, which is the FDCA.

Abstract: Methods for alleviating a condition caused by abnormal subcutaneous deposit of adipose tissue or fat in a subject in need thereof an effective amount of a composition comprising a first active agent, which comprises (i) a resveratrol compound, a curcumin compound, a quercetin compound, a puerarin compound, or a combination thereof, and (ii) a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides a pharmaceutical composition for reducing localized fat, comprising a pharmaceutically acceptable aqueous solution, drug-containing micelles made of surfactants, and resveratrol encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high fat tissue bioavailability, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: A bicycle saddle includes a stack of fiber fabrics, a braided fiber bundle including two bundle segments, and a cured member. The cured member includes a first cured portion and a second cured portion. The first cured portion is configured to embed the stack of fiber fabrics therein to form a shell having a front nose portion and a rear widened portion. The second cured portion is bonded to and integrally formed with the first cured portion, and is configured to embed the braided fiber bundle therein to form two rails which respectively have the bundle segments therein. A method for making the bicycle saddle is also disclosed.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: A hub motor assembly includes a hub axle, a hub shell, a motor unit, a cycloidal speed reducer, and a one-way clutch unit. When an output shaft of the motor unit rotates in a first direction about an axial line, a cycloidal wheel of the cycloidal speed reducer is driven to produce an eccentric cycloidal motion relative to the axial line, to thereby drive rotation of the hub shell in the first direction. When the output shaft rotates in a second direction opposite to the first direction, the hub shell is prevented from rotating with the output shaft.

Abstract: A hub motor assembly includes a hub axle, a hub shell, a motor unit, a cycloidal speed reducer, and a one-way clutch unit. When an output shaft of the motor unit rotates in a first direction about an axial line, a cycloidal wheel of the cycloidal speed reducer is driven to produce an eccentric cycloidal motion relative to the axial line, to thereby drive rotation of the hub shell in the first direction. When the output shaft rotates in a second direction opposite to the first direction, the hub shell is prevented from rotating with the output shaft.